ST. LOUIS, Mo. – Health care startup Epharmix is building on its clinically proven SMS-based adherence technology and looking to scale up as quickly as possible.
Epharmix uses automated text messages and phone calls to help people with chronic diseases better manage their condition and improve outcomes.
“We’re just going to continue to advance the research and build out our portfolio,” said Jason Roche, growth engineer at Epharmix, which is currently partnering with several large health systems.
The company was recently selected as one of seven health care startups for Dreamit Health’s ninth cohort. The 14-week accelerator program provides one-on-one coaching, opportunities to pitch to dozens of potential customers, meet with top-tier venture funds and gain access to a network of Dreamit alumni and other resources.
Epharmix’s technology has been clinically proven to drive lasting patient engagement and improve adherence through several published papers including the Journal of Medical Internet Research, Scientific Reports and JMIR Diabetes.
“Patients don’t always have the time to troubleshoot Bluetooth devices or walk through new mobile applications,” said Roche. “Our technology collects patient-reported outcomes in a form patients and providers understand most—phone calls and text messages.”
Epharmix’s system automatically collects biometrics and symptoms for 24 disease states and several chronic conditions. Roche said the technology is currently being used in 10 different states and is live on 100 platforms, with a focus on medically underserved patients in the home who are hard to engage.
“The technology is helping health care to move into a ‘true value’ space,” Roche said. “With increasing connectivity, clinicians can oversee more patients.”